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Abstract
Introduction. Canine cutaneous round cell tumours (CCRCTs) include various benign and malignant neoplastic 
processes. Due to their similar morphology, the diagnosis of CCRCTs based on histopathological examination 
alone can be challenging, often necessitating ancillary immunohistochemical (IHC) analysis. This study presents 
a retrospective analysis of CCRCTs.
Materials and methods. This study includes 60 cases of CCRCTs, including 55 solitary and 5 multiple tumours, 
evaluated immunohistochemically using a basic antibody panel (MHCII, CD18, Iba1, CD3, CD79a, CD20 and 
mast cell tryptase) and, when appropriate, extended antibody panel (vimentin, desmin, a-SMA, S-100, melan-A 
and pan-keratin). Additionally, histochemical stainings (May-Grünwald-Giemsa and methyl green pyronine) 
were performed.
Results. IHC analysis using a basic antibody panel revealed 27 cases of histiocytoma, one case of histiocytic 
sarcoma, 18 cases of cutaneous lymphoma of either T-cell (CD3+) or B-cell (CD79a+) origin, 5 cases of plas-
macytoma, and 4 cases of mast cell tumours. The extended antibody panel revealed 2 cases of alveolar rhabdo-
myosarcoma, 2 cases of amelanotic melanoma, and one case of glomus tumour.
Conclusions. Both canine cutaneous histiocytoma and cutaneous lymphoma should be considered at the beginning 
of differential diagnosis for CCRCTs. While most poorly differentiated CCRCTs can be diagnosed immunohis-
tochemically using 1–4 basic antibodies, some require a broad antibody panel, including mesenchymal, epithelial, 
myogenic, and melanocytic markers. The expression of Iba1 is specific for canine cutaneous histiocytic tumours, 
and more sensitive than CD18. The utility of CD20 in the diagnosis of CCRCTs is limited. (Folia Histochemica 
et Cytobiologica 2019, Vol. 57, No. 3, 146–154)
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Introduction
Canine cutaneous round cell tumours (CCRCTs) 
are a heterogeneous group of neoplastic processes 
of similar morphology, but various histologic origins, 
with essentially different prognoses as well as treat-
ments. CCRCTs generally include canine cutaneous 
histiocytoma, cutaneous lymphoma, plasmacytoma, 
and poorly differentiated mast cell tumours [1, 2], but 
some authors have also included amelanotic melano-
ma, neuroendocrine tumour, transmissible venereal 
tumour, and histiocytic sarcoma in this group [3–5]. 
Due to the similar morphology of tumour cells, rou-
tine histopathological examinations are not sufficient 
to obtain proper diagnoses in many cases of CCRCTs. 
Furthermore, veterinary oncologists require more 
specific diagnoses, which are essential for further 
therapy [6]. Some studies have shown that the histo-
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pathological diagnosis of a significant percentage of 
CCRCTs was modified after immunohistochemical 
(IHC) analysis [1, 7, 8]. 
The antibody panel for CCRCTs, described by Fer-
nandez et al. (2005), includes MHCII, CD18, lympho-
cytic markers (CD3, CD79a), and mast cell tryptase 
[1]. While CD3, CD79a, and mast cell tryptase are 
highly specific for T-cell lymphoma, B-cell lymphoma/ 
/plasmacytoma, and mast cell tumours, respectively, 
MHCII and CD18 can be expressed by a wide range 
of cells [9, 10]. Although the immunoexpression of 
neither MHCII nor CD18 is specific for Langerhans 
cells of histiocytoma, the immunoexpression of both 
markers indicates histiocytoma, but only if tumour 
is negative for both CD3 and CD79a [1]. Recently, 
ionized calcium-binding adapter molecule 1 (Iba1), 
a pan-macrophage marker expressed by all subpop-
ulations of cells of the monocyte/macrophage line-
age, was shown to be specific for various cutaneous 
histiocytic disorders, including canine cutaneous 
histiocytoma and histiocytic sarcoma [11].
The diagnosis of cutaneous lymphoma is based 
on the immunoexpression of either CD3 or CD79a. 
While CD3 is a common marker of all T-cells [12], 
CD79a is an a-chain of the transmembrane heterod-
imer CD79, which is expressed exclusively by B-cells. 
In humans, the expression of CD79a continues 
throughout the phase of terminal plasma cell differ-
entiation [13]. It was previously shown that 56–80% of 
canine plasmacytomas express CD79a [14, 15]. CD20, 
a phosphoprotein expressed from the pre-B cell stage 
to the activated B-cell stage, is also suitable for canine 
lymphoma immunophenotyping [16], but is rarely 
expressed in canine plasmacytomas [15]. 
Mast cell tryptase belongs to the group of mast 
cell-specific proteases that are expressed exclusively 
by mast cells [17] and are widely used as markers of 
these cells [18, 19]. Tryptase immunostaining shows 
high sensitivity for the detection of both normal and 
atypical mast cells, as shown in studies of human 
mastocytosis and other diseases associated with an 
increase in mast cells [19]. A previous report revealed 
that immunoperoxidase staining with monoclonal an-
tibody AA1 (anti-tryptase) is both highly specific and 
sensitive for the detection of mast cells in routinely 
processed tissues [18].
The first aim of this study was to evaluate the utility 
of histochemical and immunohistochemical assess-
ments in the diagnosis of CCRCTs. The second aim 
of this study was to identify tumours that should be 
considered at the beginning of differential diagnosis 
in cases of CCRCTs and tumours that are rare and 
unexpected but still possible. A properly structured list 
of conditions to be considered in differential diagnosis 
will allow the development of a cost-effective stepwise 
approach for the complementary immunohistochem-
ical analysis of CCRCTs.
Materials and methods
The canine cutaneous tumours analysed in this study were 
archival diagnostic specimens (2013–2017) from the De-
partment of Pathological Anatomy, Faculty of Veterinary 
Medicine, University of Warmia and Mazury in Olsztyn, 
Poland. Cutaneous tumours (solitary n = 55 and multiple 
n = 5) were collected from 59 dogs by surgical excisional or 
incisional biopsies. The tissue samples were fixed in 10% buff-
ered formalin, embedded in paraffin, cut into 3-µm sections, 
and mounted onto silanized glass slides. The sections were 
processed routinely and stained with Mayer’s haematoxylin 
and eosin (HE). All tumours were diagnosed originally by 
histopathologic examination, as undifferentiated round cell 
tumours, without specifying the tumour type. Due to the 
lack of features indicating the specific tumour type, a more 
definitive diagnosis was not obtained. Immunohistochemical 
examination of each tumour was performed manually using 
a basic antibody panel (MCHII, CD18, Iba1, CD3, CD79a, 
CD20 and mast cell tryptase) and a visualization system based 
on the immunoperoxidase method with 3,3-diaminobenzidine 
(DAB) as a substrate (Table 1). In cases where the final diag-
nosis could not be determined on the basis of the results of the 
basic antibody panel, an extended antibody panel was applied 
(vimentin, desmin, a-SMA, S-100, melan-A and pan-keratin; 
Table 1). The specimens were counterstained with Mayer’s 
haematoxylin. For the positive control, normal canine tissues 
(tonsil for MHCII, CD18, Iba1, CD3, CD79a and CD20; 
colon for vimentin, desmin, a-SMA, and S-100; and skin for 
mast cell tryptase, melan-A and pan-keratin) were processed 
together with the evaluated sections. For the negative control, 
the primary antibody was replaced by the isotype-matched 
mouse IgG (Dako, Glostrup, Denmark) at the appropriate 
dilution (for monoclonal primary antibodies) or omitted (for 
polyclonal primary antibodies). Additionally, selected slides 
were stained using May-Grünwald-Giemsa (MGG staining 
kit; Bio-Optica, Milan, Italy), methyl green pyronine (MGP 
staining kit; Bio-Optica), or periodic acid-Schiff (Sigma-Al-
drich, Steinheim, Germany). 
The slides were evaluated using an Olympus BX51 
light microscope (Olympus, Hamburg, Germany), and the 
microphotographs were prepared using the U-TVO.5XC-3 
camera and cell˄B imaging software (both Olympus).
Results
All evaluated cutaneous tumours comprised a dense 
infiltration of round to polygonal cells with variable 
(low to fairly high) anisocytosis, anisokaryosis and 
chromatin distribution. The mitotic activity of the 
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tumour cells also varied from low to high. The ma-
jority of the evaluated tumours (55/60, 91.7%) were 
differentiated using the basic antibody panel. The 
detailed basic results of IHC analyses are presented 
in Table 2.
Canine cutaneous histiocytoma was diagnosed 
in 27/60 tumours (45%), collected from dogs aged 
8 months to 12 years (mean age: 6.4). The tumours 
were solitary except for one case (a 1.5-year old dog 
presented with multiple tumours localized within the 
pinna). The tumour cells expressed MHCII, Iba1, 
and — in 23 cases — CD18, but were negative for 
CD3, CD79a, CD20 and mast cell tryptase (Fig. 1A). 
The tumour cells showed moderate epitheliotropism, 
which was difficult to observe in massively ulcerated 
tumours. In one dog, the cutaneous tumour of the 
paw pad showed a morphology similar to that of 
the simultaneously excised testicular tumour, which 
was diagnosed morphologically as seminoma, and 
therefore cutaneous metastasis of seminoma was 
suspected. Tumour cells massively infiltrated skin and 
subcutis, without any epitheliotropism. However, the 
IHC assessment revealed, that the neoplastic cells 
of the cutaneous tumour showed the membranous 
expression of MHCII and Iba1 (while the testicular 
tumour was negative to Iba1, but approximately 10% 
of tumour cells expressed MHCII), and were negative 
to CD18, CD3, CD79a, CD20 and mast cell tryptase. 
On the basis of these findings, histiocytic sarcoma was 
diagnosed (Fig. 1B).
Cutaneous lymphomas of either T-cell or B-cell 
origin were diagnosed in 18/60 cases (30%). These 
tumours were collected from dogs aged 1.5–13 years 
(mean age: 8.8 years). In 14 cases, cutaneous lym-
phoma was solitary, while in 4 — multiple (epithelio-
tropic T-cell lymphoma). In epitheliotropic cutaneous 
lymphomas (10/60 cases, 16.7%), the tumour cells 
showed prominent epitheliotropism. The tumour 
cells expressed either CD3 (9/60 cases, 15%, Fig. 1C) 
or CD79a (one case). In nonepitheliotropic cutaneous 
Table 1. Primary antibodies and antigen retrieval and visualization systems
Primary antibody Clone Dilution Antigen retrieval Visualization system
HLA-DR a chain
(MHCII)a
Monoclonal mouse anti-human 
TAL.1B5
1:20 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP,  
Mouse (DAB)a
CD18c Monoclonal mouse anti-canine 
CA16.3C10
1:10 5 min.  
proteinase Ka
EnVision+ System-HRP, Mouse (DAB)a
Iba1d Polyclonal rabbit 1:500 Tris-EDTA buffer 
pH = 9b
ImmPRESS HRP Universal Antibody 
(Anti-Mouse/Rabbit IgG)e
CD3a Polyclonal rabbit anti-human 1:50 Tris-EDTA buffer 
pH = 9b
ImmPRESS HRP Universal Antibody 
(Anti-Mouse/Rabbit IgG)e
CD79af Monoclonal mouse anti-human 
HM57
1:100 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
CD20g Monoclonal rabbit anti-human 
SP32
1:100 Tris-EDTA buffer 
pH = 9b
ImmPRESS HRP Universal Antibody 
(Anti-Mouse/Rabbit IgG)e
Mast cell tryptasea Monoclonal mouse anti-human 
AA1
1:200 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
Vimentina Monoclonal mouse anti-bovine  
VIM 3B4
1:100 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
Desmina Monoclonal mouse anti-human 
D33
1:50 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
a-SMAa Monoclonal mouse anti-human 
1A4
1:50 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
S-100a Polyclonal rabbit anti-bovine 1:50 Citrate buffer  
pH = 6b
ImmPRESS HRP Universal Antibody 
(Anti-Mouse/Rabbit IgG)e
Melan-Af Mouse anti-human A103 1:50 Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
Pan keratinh Monoclonal mouse anti-human 
AE1/AE3/PCK26
ready to use Tris-EDTA buffer 
pH = 9b
EnVision+ System-HRP, Mouse (DAB)a
aDako, Glostrup, Denmark; bAntigen retrieval was heat-induced, conducted in a microwave oven at 650 W. Samples were microwaved twice to the 
boiling point, and incubated in a hot buffer for 20 min after boiling each time; cPF. Moore, Davis, CA, USA; dWako Pure Chemical Industries, 
Ltd., Osaka, Japan; eVector Laboratories Inc., Burlingame, CA, USA; fBio-Rad Laboratories Inc., Hercules, CA, USA; gAbcam, Cambridge, UK; 
hVentana, Tucson, AZ; USA.
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Table 2. Basic antibody panel results in the evaluated canine cutaneous round cell tumours 
No MHCII CD18 Iba1 CD3 CD79a CD20 Tryptase Diagnosis
1 + + + – – – – Histiocytoma
2 + + + – – – – Histiocytoma
3 + + + – – – – Histiocytoma
4 + + + – – – – Histiocytoma
5 + + ND – – ND – Histiocytoma
6 + + ND – – ND – Histiocytoma
7 + + + – – – – Histiocytoma
8 + + + – – – – Histiocytoma
9 + + + – – – – Histiocytoma
10 + + + – – – – Histiocytoma
11 + + + – – – – Histiocytoma
12 + + + – – – – Histiocytoma
13 + + ND – – ND – Histiocytoma
14 + + + – – – – Histiocytoma
15 + + + – – – – Histiocytoma
16 + + + – – – – Histiocytoma
17 + + ND – – ND – Histiocytoma
18 + + + – – – – Histiocytoma
19 + + + – – – – Histiocytoma
20 + + + – – – – Histiocytoma
21 + + ND – – ND – Histiocytoma
22 + + + – – – – Histiocytoma
23 + + + – – – – Histiocytoma
24* + + + – – – – Histiocytoma
25 + – + – – – – Histiocytoma
26 + – + – – – – Histiocytoma
27 + – + – – – – Histiocytoma
28 + – + – – – – Histiocytic sarcoma
29 + + – + – – – Epitheliotropic T-cell lymphoma
30 + – – + – – – Epitheliotropic T-cell lymphoma
31* + – – + – – – Epitheliotropic T-cell lymphoma
32* + + – + – – – Epitheliotropic T-cell lymphoma
33 + – – + – – – Epitheliotropic T-cell lymphoma
34* + + – + – – – Epitheliotropic T-cell lymphoma
35 – – – + – – – Epitheliotropic T-cell lymphoma
36 – – ND + – ND ND Epitheliotropic T-cell lymphoma
37* + + ND + – ND ND Epitheliotropic T-cell lymphoma
38 + – ND – + – – Epitheliotropic B-cell lymphoma
39 + – ND + – ND – Nonepitheliotropic T-cell lymphoma
40 – – – + – – – Nonepitheliotropic T-cell lymphoma
41 – – – + – – – Nonepitheliotropic T-cell lymphoma
42 + – – + – – – Nonepitheliotropic T-cell lymphoma
43 – – – – + – – Nonepitheliotropic B-cell lymphoma
44 – – ND – + – – Nonepitheliotropic B-cell lymphoma
Æ
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lymphomas (8/60 cases, 13.3%), the tumour cells ex-
pressed either CD3 (4 cases, 6.7%) or CD79a (4 cases, 
6.7%; Fig. 1D). The expression of CD20 was seen in 
two cases of nonepitheliotropic B-cell lymphoma. The 
expression of MHCII was observed in 8 cases of epithe-
liotropic lymphoma and 3 cases of nonepitheliotropic 
lymphoma, while the expression of CD18 — in 4 cases 
of epitheliotropic lymphoma. All evaluated lymphomas 
were negative to Iba1 and mast cell tryptase.
In cutaneous plasmacytomas (5/60 cases, 8.3%) 
collected from dogs aged 1.5–14 years (mean age: 
8.3 years), the tumour cells expressed CD79a, and, 
in one of these cases — also CD20, but the nuclear:-
cytoplasmic ratio was substantially lower than that in 
tumours diagnosed as cutaneous B-cell lymphomas. 
In four of these cases, the cytoplasm stained magenta 
with methyl green pyronine. The expression of MHCII 
was observed in 2 cases, while CD18 — in 3 cases. All 
evaluated plasmacytomas were negative to Iba1 and 
mast cell tryptase.
In four other cases (4/60, 6.7%), tumour cells ex-
pressed mast cell tryptase and were negative to other 
markers; therefore, their final diagnosis was mast cell 
tumour. The metachromatic granules, which were 
indiscernible in routine HE staining, were visualized 
by May-Grünwald-Giemsa staining in only one of 
these tumours.
The final diagnosis could not be assessed on the 
basis of the results of the basic antibody panel in 
5/60 cases (8.3%), as the tumour cells did not express 
MHCII, CD18, Iba1, CD3, CD79a, CD20 or mast 
cell tryptase.
In two of these cases (3.3%), tumour cells ex-
pressed vimentin and desmin and did not express the 
other markers, with the final diagnosis being alveolar 
rhabdomyosarcoma (Fig. 1E). In one of these dogs, 
due to the simultaneous occurrence of another tu-
mour on the forearm, multiple round cell neoplasia 
was suspected. However, after the IHC assessment, 
the other tumour was diagnosed as a histiocytoma.
In one of the evaluated tumours, the tumour cells 
expressed vimentin, S-100 and melan-A and did not 
express the other evaluated markers, with a final diag-
nosis of amelanotic melanoma. No melanin granules 
were found in the cytoplasm of the tumour cells. The 
surface of the tumour was massively ulcerated, but dis-
tinct epidermal invasion was noted. In other tumour, 
the tumour cells expressed vimentin and S-100, but 
were negative to melan-A (as well as other evaluated 
markers), and therefore amelanotic melanoma was 
suspected. Unfortunately, in this case, the size of the 
sample was not sufficient for further evaluation.
In one tumour located in the area of the lips, the tu-
mour cells expressed vimentin and a-SMA and did not 
express the other evaluated markers, and the tumour 
was finally diagnosed as a glomus tumour. Round to 
oval neoplastic cells formed small clusters surrounded 
by a PAS-positive basement membrane (Fig. 1F).
Table 2 (cont.). Basic antibody panel results in the evaluated canine cutaneous round cell tumours 
No MHCII CD18 Iba1 CD3 CD79a CD20 Tryptase Diagnosis
45 – ND ND – + + – Nonepitheliotropic B-cell lymphoma
46 + – – – + + – Nonepitheliotropic B-cell lymphoma
47 + + – – + + – Plasmacytoma
48 + – ND – + – – Plasmacytoma
49 – + ND – + – – Plasmacytoma
50 – + – – + – – Plasmacytoma
51 – – ND – + – – Plasmacytoma
52 – – ND – – ND + Mast cell tumour
53 – – – – – – + Mast cell tumour
54 – ND ND – – ND + Mast cell tumour
55 – – ND – – ND + Mast cell tumour
56 – – ND – – ND – Alveolar rhabdomyosarcoma
57 – – ND – – ND – Alveolar rhabdomyosarcoma
58 – – – – – – – Amelanotic melanoma
59 – – – – – – – Amelanotic melanoma
60 – – – – – ND – Glomus tumour
Symbols: +, positive; –, negative; ND — not determined; * multiple tumours
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In the present study, histiocytomas and cutaneous 
lymphomas constituted the vast majority (75%) of 
the evaluated tumours. Therefore, histiocytomas and 
cutaneous lymphomas should be considered at the 
beginning of the differential diagnosis of CCRCTs. 
Histiocytomas are very common in dogs [2, 20], 
while cutaneous lymphomas occur less commonly 
and represent 1% of all canine skin tumours [12, 21]. 
In the present study, only tumours posing diagnostic 
difficulties were included; therefore, the number of 
detected tumours does not reflect their occurrence 
in the population.
In the present study, multiple tumours were seen 
in 4 cases of epitheliotropic T-cell lymphoma and in 
Figure 1. Microphotographs show undifferentiated canine cutaneous round cell tumours with similar histologic presenta-
tions and various definitive diagnoses. (A) Histiocytoma. Tumour comprised uniformly polygonal cells, with a moderately 
abundant, slightly eosinophilic cytoplasm (HE). Inset: Tumour cells show cytoplasmic and membranous expression of Iba1 
(IHC, DAB). (B) Histiocytic sarcoma. Round to polygonal tumour cells with high mitotic and apoptotic rates. Morpholog-
ically, the tumour cells are similar to the testicular tumour (left inset), but these cells are packed more densely with nuclear 
crowding (HE). Right inset: Tumour cells showing the cytoplasmic and membranous expression of Iba1 (IHC, DAB). (C) 
Epitheliotropic T-cell lymphoma. Round to polygonal tumour cells with low-to-moderate anisocytosis and anisokaryosis and 
a high mitotic rate (HE). Inset: Tumour cells show the cytoplasmic expression of CD3 (IHC, DAB). (D) Nonepitheliotropic 
B-cell lymphoma. Tumour comprised uniformly round cells with low anisocytosis and anisokaryosis and small-to-moderate 
amounts of cytoplasm (HE). Inset: Tumour cells show the cytoplasmic expression of CD79a (IHC). (E) Alveolar rhabdo-
myosarcoma. Polygonal tumour cells with moderate anisocytosis and anisokaryosis form clusters separated by thin, highly 
vascularized fibrous septa (HE). Inset: Tumour cells show the cytoplasmic expression of desmin (IHC, DAB). (F) Glomus 
tumour. Small clusters of tumour cells are surrounded by a PAS-positive basement membrane (PAS). Inset: Immunoreactivity 
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one case of histiocytoma. While epitheliotropic T-cell 
lymphoma has a wide range of clinical presentations, 
and primary skin lesions, even if solitary, mostly pro-
gress into disseminated or generalized disease [12], 
multiple histiocytoma is very rare and occurs in less 
than 1% of the cases [22]. However, other CCRCTs, 
including non-epitheliotropic lymphoma, mast cell 
tumour and plasmacytoma, can also present as mul-
tiple tumours [21, 23, 24]. 
Epitheliotropism is an important diagnostic fea-
ture of some types of CCRCTs, allowing clinicians 
to narrow the list of possible diagnoses. The ability 
of tumour cells to invade and infiltrate the epidermis 
and/or adnexa results from the expression of specific 
adhesion molecules [25, 26]. Distinct epitheliotropism 
is highly indicative for epitheliotropic lymphoma and 
histiocytoma, but can be also seen in melanoma [2], 
and was reported in a few cases of mast cell tumour 
[26]. In the present study, epitheliotropism was 
a distinct feature of epitheliotropic lymphoma, but 
was also noted in most cases of histiocytoma and 
one case of amelanotic melanoma. However, the 
presence versus the lack of epitheliotropism should be 
interpreted with caution, as some authors claim that 
epitheliotropism of the epitheliotropic lymphoma may 
be reduced in association with progressive and severe 
dermal invasion [12]. Nevertheless, epitheliotropism 
is usually still prominent in canine tumour-stage 
mycosis fungoides, unlike its human equivalent [25]. 
Furthermore, the characteristic packets of tumour 
cells within the epidermis are not easy to detect in 
massively ulcerated tumours, as seen in the present 
study and in previous reports [8, 27]. 
The results of the present study indicate, that 
expression of Iba1 is specific for canine histiocytic 
tumours, what was also reported previously [11]. In 
the present study, expression of both MHCII and 
CD18 was not specific for histiocytoma, and was seen 
also in 4 cases of epitheliotropic T-cell lymphoma and 
one case of plasmacytoma. Furthermore, in 4 cases 
of histiocytoma and a histiocytic sarcoma, tumour 
cells were negative to CD18. The previous report 
revealed, that significant number of histiocytomas 
showed CD18 expression in only a small number of 
the tumour cells [8]. Therefore, we suggest, that Iba1 
can easily replace both MHCII and CD18 in the basic 
antibody panel for the diagnosis of CCRCTs.
In the present study, the expression of CD20 was 
reported in two cases of nonepitheliotropic B-cell 
lymphoma and one case of plasmacytoma, so its sensi-
tivity in identifying tumours of B-cell origin was much 
lower, than CD79a. Although CD20 is a valuable aid 
in immunophenotyping of canine lymphomas [16], the 
utility of this marker in diagnosing CCRCTs seems to 
be limited. Furthermore, it has been shown recently, 
that expression of CD20 in canine epitheliotropic 
T-cell lymphoma is not uncommon [28]. In the present 
study, one of the epitheliotropic lymphomas expressed 
CD79a and did not express CD3. Although epitheli-
otropic lymphomas are regarded to be exclusively of 
T-cell origin [21, 29], there is one report describing 
a B-cell epitheliotropic lymphoma [1]. 
The diagnosis of plasmacytoma in the present 
study was based on the immunoexpression of CD79a 
and the morphology, as the expression of CD79a alone 
cannot be used to distinguish B-cell lymphomas from 
plasmacytomas [1, 7]. All evaluated plasmacytomas 
expressed CD79a, and most of them (except for one) 
stained positive for MGP. Therefore, MGP staining 
can be used as an adjunct to the diagnosis of plasma-
cytomas, but cannot replace immunohistochemical 
markers. In a previous study, the antibody Mum-1p, 
used to detect multiple myeloma 1/interferon regu-
latory factor 4 (MUM1/IRF-4) antigen, was proven 
to be specific for canine plasmacytomas, superior in 
both sensitivity and specificity to CD79a [15]. Howev-
er, the expression of MUM1/IRF-4 was also recently 
described in canine cutaneous histiocytomas, and 
therefore, this immunolabelling is recommended to 
be used only as a part of the round cell tumour panel, 
not alone [30]. 
Mast cell tumours frequently occur in dogs, and 
their diagnosis is usually straightforward due to the 
presence of characteristic, metachromatic granules 
in the cytoplasm of the tumour cells, which are easily 
identifiable with histochemical stains [31]. However, 
these granules are occasionally difficult to detect in 
some subsets of poorly differentiated mast cell tu-
mours [32]. In the present study, the metachromatic 
granules were detected by histochemical staining 
(MGG) in only one of the four poorly differentiated 
mast cell tumours, but all of these tumours showed 
positive findings for mast cell tryptase. Therefore, 
mast cell tryptase immunolabelling should be consid-
ered superior in sensitivity to histochemical stainings 
for the identification of canine mast cell tumours. 
However, mast cell tumours that did not express 
tryptase but showed positivity for toluidine blue were 
previously described [1, 33]. Thus, the combination 
of mast cell tryptase immunolabelling and one of the 
histochemical stainings for metachromatic granule 
visualization would be the most appropriate method 
for the diagnosis of poorly differentiated mast cell 
tumours. 
Amelanotic melanomas can be diagnostically 
challenging, as the cellular features of neoplastic 
cells may mimic poorly differentiated carcinomas, 
soft tissue sarcomas, and lymphomas [27, 34]. In the 
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present study, one case of CCRCT was diagnosed as 
amelanotic melanoma based on the immunoexpres-
sion of vimentin, S-100 and melan-A. In the other 
case, tumour cells expressed vimentin and S-100, 
but were melan-A negative. The expression of both 
vimentin and S-100 is not specific for melanocytes 
[34], and therefore the final diagnosis in that case was 
not obtained. However, the amelanotic melanoma can 
be suspected, as other possible differential diagnoses 
were excluded by other immunohistochemical stain-
ings. In this case, other melanocytic markers should be 
applied, such as antibody PNL2, which was shown to 
be more sensitive than melan-A in the identification 
of canine melanocytic neoplasms [27, 35]. 
Other round cell tumours included in the present 
study, i.e., alveolar rhabdomyosarcoma and glomus 
tumour, are not usually included in the differential 
diagnosis of CCRCTs. However, alveolar rhabdomyo-
sarcoma can manifest as a cutaneous lesion, as de-
scribed in a previous study [36]. In contrast to alveolar 
rhabdomyosarcoma, which, in our opinion, should be 
always included in the differential diagnosis of poorly 
differentiated CCRCTs (negative to basic antibody 
panel), glomus tumours seem to be extremely rare. 
Glomus tumours are benign neoplasms derived from 
glomus cells and are found frequently in humans but 
have been described in only single case reports in 
dogs [37–40]. 
In conclusion, histiocytoma and cutaneous lym-
phoma should be considered at the beginning of dif-
ferential diagnosis of poorly differentiated CCRCTs. 
The expression of Iba1 is specific for canine cutane-
ous histiocytic tumours (including histiocytoma and 
histiocytic sarcoma), and more sensitive than CD18. 
The utility of CD20 in the diagnosis of CCRCTs is 
limited. Although most undifferentiated CCRCTs 
can be diagnosed immunohistochemically using 1–4 
basic antibodies, some require a broad antibody panel, 
including mesenchymal, epithelial, myogenic, and 
melanocytic markers. Clinicians should also take into 
account the fact that many different types of CCRCTs 
can be morphologically indistinguishable from each 
other, and immunohistochemistry should be routinely 
recommended to confirm the morphological diagno-
sis, especially when there are discrepancies between 
the diagnosis and the clinical picture of the disease.
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